Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7186 AL 7200

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease

Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X.

Curr Alzheimer Res. 2012 Jul;9(6):746-58. doi: 10.2174/156720512801322564.

Effects of natural antioxidants in neurodegenerative disease

Albarracin SL, Stab B, Casas Z, Sutachan JJ, Samudio I, Gonzalez J, Gonzalo L, Capani F, Morales L, Barreto GE.

Nutr Neurosci. 2012 Jan;15(1):1-9. doi: 10.1179/1476830511Y.0000000028.

Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings

Serretti A, Olgiati P.

CNS Neurol Disord Drug Targets. 2012 May;11(3):299-305. doi: 10.2174/187152712800672472.

NADPH oxidases: novel therapeutic targets for neurodegenerative diseases

Gao HM, Zhou H, Hong JS.

Trends Pharmacol Sci. 2012 Jun;33(6):295-303. doi: 10.1016/j.tips.2012.03.008. Epub 2012 Apr 11.

The pharmacological properties and therapeutic use of apomorphine

Ribarič S.

Molecules. 2012 May 7;17(5):5289-309. doi: 10.3390/molecules17055289.

Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase

Priyadarshini M, Kamal MA, Greig NH, Reale M, Abuzenadah AM, Chaudhary AG, Damanhouri GA.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):482-9. doi: 10.2174/187152712800792767.

Target-based selection of flavonoids for neurodegenerative disorders

Jones QR, Warford J, Rupasinghe HP, Robertson GS.

Trends Pharmacol Sci. 2012 Nov;33(11):602-10. doi: 10.1016/j.tips.2012.08.002. Epub 2012 Sep 12.

Pharmacological treatment of dementia

Schwarz S, Froelich L, Burns A.

Curr Opin Psychiatry. 2012 Nov;25(6):542-50. doi: 10.1097/YCO.0b013e328358e4f2.

The unravelling of metabolic dysfunctions linked to metal-associated diseases by blue native polyacrylamide gel electrophoresis

Han S, Auger C, Castonguay Z, Appanna VP, Thomas SC, Appanna VD.

Anal Bioanal Chem. 2013 Feb;405(6):1821-31. doi: 10.1007/s00216-012-6413-9. Epub 2012 Sep 22.

Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand

Kulkantrakorn K, Tanyakitpisal P, Towanabut S, Dejthevaporn C, Rangseekajee P, Pongpakdee S, Laptikultham S, Rodprasert K, Setthawatcharawanich S, Thinkhamrop B.

Psychogeriatrics. 2013 Mar;13(1):1-8. doi: 10.1111/j.1479-8301.2012.00403.x. Epub 2012 Feb 17.

Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease

Collins LE, Paul NE, Abbas SF, Leser CE, Podurgiel SJ, Galtieri DJ, Chrobak JJ, Baqi Y, Müller CE, Salamone JD.

Pharmacol Biochem Behav. 2011 Sep;99(3):414-22. doi: 10.1016/j.pbb.2011.05.026. Epub 2011 May 27.

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group.

Arch Gen Psychiatry. 2011 Aug;68(8):853-61. doi: 10.1001/archgenpsychiatry.2011.72.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias